BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to ...
Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...
Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. This is an ASCO Meeting Abstract from the 2025 ...
The global market for healthcare predictive analytics is expected to grow from $16.7 billion in 2025 and is projected to reach $50.4 billion by the end of 2030, at a compound annu ...
Update (Oct. 1, 00:30 UTC): This article has been updated to include comments from DNA Fund co-founder Chris Miglino. Predictive Oncology (POAI), a biotechnology company specializing in AI-driven ...
Predictive Oncology, Inc. (NASDAQ:POAI) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types. The Details: The models were ...
There is a vast array of predictive analytics tools, but not all are created equal. Software differs widely in terms of capability and usability — not all solutions can address all types of advanced ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback